From: Nanotoxicological profiles of clinically approved nanoplatforms
Formulation composition | Preparation method | Dose (administration route) | Animal/cell type | Cell/tissue target | Biocompatibility-/toxicity-related outcomes | References |
---|---|---|---|---|---|---|
In vitro studies | ||||||
Fluorescein amine-labelled PLGA mixed with ε-caprolactone–PEG copolymers | Nanoprecipitation technique–solvent evaporation | 18–180 μg/mL | L929 cell line | Mouse fibroblasts | PLGA-based NPs exhibited no changes in fibroblasts morphology and confluent monolayer after 48-h incubation, while dendrimers led to altered morphology and detachment in a dose-dependent way | Do et al. [30] |
Gold NPs-coated polydopamine-modified PLGA capsule hybrid | Double emulsion, solvent evaporation | 10–1000 μg/mL | ECA-109 cell line | Human oesophageal cancer cell | No remarkable cytotoxicity: cell viability was same as the control cells treated with PBS over 24 h | Xi et al. [149] |
Monomethoxy-PEG-PLGA-poly(L-lysine) NPs | One-step oil-in-water emulsion, solvent evaporation | 10–1000 μM | RAW 264.7, Huh7 and L02 cells | Murine macrophage, human hepatic carcinoma and normal embryo liver cells | No effect on cell membrane integrity, protein synthesis and chromatin stability, except dose-dependent and time-dependent increase in the content of reactive oxygen species. No significant induction of inflammatory cytokines | He et al. [55] |
folic-acid-grafted-PEG-PLGA NPs co-loaded with cisplatin and paclitaxel | One-step oil-in-water emulsion, solvent evaporation | 0.01–1 mg/mL | New Zealand white rabbits’ blood; M109 and A549 cells | Rabbit erythrocyte, murine and human lung carcinoma cell | Drug-free NPs exhibited no overt cytotoxicity, haemolysis, blood clotting or complement activation | He et al. [53] |
Amphotericin B-loaded PLGA NPs decorated with dimercaptosuccinic acid ligand | Water-in-oil emulsification, solvent evaporation | 1.56–600 μg/mL | Human blood and peritoneal tissues | Erythrocyte and peritoneal macrophages | Drug-loaded NPs were less haemolytic than plain drug. NPs showed no cytotoxicity, while free drug was toxic | Souza et al. [130] |
Biotin/lactobionic acid-modified PEG-PLGA-PEG NPs co-loaded with curcumin and 5-fluorouracil | Nanoprecipitation technique–solvent evaporation | 50–800 μg/mL | Hep G2 and HL 7702 cells | Human hepatocytes and hepatoma cells | Unlike drug-loaded NPs, the blank NPs showed no overt cytotoxicity after 48 h of incubation | Ni et al. [97] |
Didodecyldimethylammonium bromide (DMAB)-stabilized PLGA modified with polyvinyl alcohol (PVA) or PEG | One-step oil-in-water emulsion, solvent evaporation | 0.5–1000 μg/mL | Caco-2 cell line | Human epithelial colorectal adenocarcinoma cells | DMAB-PLGA NPs modified with PVA or PEG showed no cytotoxicity, while unmodified NPs induced significant concentration-dependent necrosis, apoptosis and chromatin disturbance | Gossmann et al. [46] |
PLGA-poly(3-hydroxybutyrate) nanocomposite extract | Needle-punching non-woven fabric synthesis catalysed by Zr(AcAc)4 | Not indicated | Fibroblast-like cell line L929 | Mouse fibroblast | No cytotoxic or genotoxic effects were observed following 72Â h of incubation | Krucinska et al. [73] |
PLGA NPs loaded with TRITC-in-polyethyleneimine | Double emulsion, solvent evaporation | Not indicated | Male and female gametes | Sperms, oocytes | No distinct morphological, chromosomal abnormalities, transgenerational effects or genetic aberrations were observed | Kim et al. [70] |
PLGA-(poly-L-orithine/fucoidan) core–shell NPs | One-step oil-in-water emulsion, solvent evaporation | 5–100 µg/mL | MCF-10A cell line | Breast epithelium cells and rabbit blood cells | Cell morphology was unchanged, but proliferation pattern was affected in a time-dependent way. Haemolysis rates increased with NPs concentrations | Cai et al. [21] |
PLGA NPs | Nanoprecipitation, solvent evaporation | 0.1–0.4 mg/ml | Primary human myoblasts and myotubes | Skeletal tissues | PLGA NPs did not decrease cell viability, while liposomes and silica NPs showed concentration-dependent and time-dependent decrease in cell viability | Guglielmi et al. [49] |
PEG-PLGA, PEG-poly(L-lactide) (PLA) and PEG-PLA-PEG NPs | One-step oil-in-water emulsion, solvent evaporation | 0.05–1 mg/ml | Fibroblast-like cell line L-929 and human umbilical vein endothelial cell | Mouse fibroblasts, blood, human macrophages and human vascular endothelium | No significant cytotoxicity observed. Adverse effects of PEG-PLGA NPs on haemolysis and inflammatory cytokines release were the highest while PEG-PLA-PEG NPs’ were the lowest | Shen et al. [125] |
PLGA NPs loaded with Chondroitinase ABC (ChABC) | Double emulsion, solvent evaporation | 1500–6000 µg/mL | Olfactory ensheathing cells | Rat olfactory mucosa | Following 48 h of incubation, there were no significant differences between the control and NP-treated cell viability | Azizi et al. [11] |
Chitosan-coated PLGA nanoparticles loaded with bevacizumab | One-step oil-in-water emulsion, solvent evaporation | Not reported | Fertilized fresh hen’s eggs | Hen’s egg chorioallantoic membrane | NPs formulation was non-irritant and tolerated to chorioallantoic membrane after | Pandit et al. [104] |
Cell-penetrating peptides decorating DNA-loaded PLGA nanoparticles | Double emulsion-solvent evaporation method | 0.075–1.2 mg/mL | A549 and Beas-2B cells | Lung tissues | After 24-h incubation of NPs with cells, there was no change in mitochondrial activity and membrane integrity In addition, the inflammatory response and levels of apoptosis were significantly lower, and there was no activation of caspase-3 | Dos Reis et al. [32] |
In vivo studies | ||||||
Monomethoxy-PEG-PLGA-poly(L-lysine) NPs | One-step oil-in-water emulsion, solvent evaporation | 10–1000 μM | Zebrafish embryos | Heart | No effect on embryonic heartbeat rate, malformation or survival. At extreme concentrations (> 500 μM), NPs induced reactive oxygen species production at early stage of embryonic development | He et al. [54] |
PLGA-poly(3-hydroxybutyrate) nanocomposite bone implant | Needle-punching non-woven fabric synthesis catalysed by Zr(AcAc)4 | Surgical femur implantation | New Zealand breed male and female rabbits | Blood, RES organs, stomach, small and large intestine, testes, uterus, heart | The blood cells remained unchanged. No significant differences between enzymes values from the test and control groups following 180Â days of implantation | Krucinska et al. [73] |
Biotin/lactobionic acid-modified PEG-PLGA-PEG NP | Nanoprecipitation, solvent evaporation | 200Â mg/kg every 2Â h (IV) | Female nude balb/c mice | Liver, spleen, kidneys, lunges and heart | No obvious signs of cellular or organ injury or inflammation were observed, and no death was recorded after injection of up to 2000Â mg/kg in total | Ni et al. [97] |
PLGA NPs loaded with TRITC-in-polyethyleneimine | Double emulsion-solvent evaporation method | Not indicated | ICR mice | Murine embryos | No influence on embryo development to the blastocyst | Kim et al. [70] |
Amphotericin B-loaded PLGA and PLGA-PEG blend NPs | One-step oil-in-water emulsion, solvent evaporation | 10Â mg/kg/day (oral or IP) | Male Wistar rat | Liver, kidneys and blood cells | Biochemical and histopathological parameters remained unchanged after 7Â days of treatment. Unlike the plain drug, NPs showed no blood cell damage | Moraes Moreira Carraro et al. [93] |
Amphotericin B-loaded PLGA NPs decorated with dimercaptosuccinic acid ligand | Water-in-oil emulsification, solvent evaporation | 6 or 30Â mg/kg/day (IP) | Healthy balb/c or Swiss mice | Blood, peritoneal, bone marrow cells | No significant difference between the DNA from mice treated with NPs and PBS, while control (cyclophosphamide) caused DNA damage. NPs showed similar neutrophils, leucocytes and monocytes as PBS, unlike the plain drug | Souza et al. [130] |
PLGA-(poly-l-orithine/fucoidan) core–shell NPs | One-step oil-in-water emulsion, solvent evaporation | 300 mg/kg (IP) | SPF mice | Liver and kidney | NPs showed no significant differences with negative control in body weight and histological parameters. No death or apparent toxicity was observed | Cai et al. [21] |
PEG-PLGA, PEG-poly(L-lactide) (PLA) and PEG-PLA-PEG NPs | One-step oil-in-water emulsion, solvent evaporation | 0.05–1 mg/ml | Zebrafish embryos | Heart and yolk sac | The concentration-dependent adverse effects of PEG-PLGA NPs on embryo survival and growth were the highest, while PEG-PLA-PEGs were lowest | Shen et al. [125] |
PLGA NPs and surface-modified PLGA chitosan NPs | One-step oil-in-water emulsion, solvent evaporation | 12Â mg/kg/day (oral) | F344 rats | Spleen, kidney, liver, lung, brain, intestine, heart | No significant histological changes seen in tested organs, except for intestine and liver. Body weight remained unchanged | Navarro et al. [96] |
Doxorubicin-loaded PLGA nanoparticles coated with poloxamer 188 | Double emulsion-solvent evaporation technique | 0.15–0.22 mg/kg/day (IV) | Chinchilla rabbits | Blood, Spleen, kidney, liver, lung, brain, intestine, heart | PLGA NPs significantly lowered the haematological, cardiac and testicular toxicity of the drug, but dose-dependent functional and morphological abnormalities were observed | Pereverzeva et al. [111] |
Cx43MP peptide loaded PLGA nanoparticles | Nanoprecipitation technique–solvent evaporation | 10–500 µg/mL | Zebrafish embryo toxicity (ZET) model | Embryos | Zebrafish remained normal 144 h after fertilization with the NPs; no significant malformations or cytotoxicity were obvious | Bisht and Rupenthal [17] |
PLGA nanoparticles | Sonication method | 100 μg/ml | BALB/c mice | Mouse cortical neuronal tissue | PLGA nanoparticles greatly protected neuronal cells against the aggregation of amyloid β (Aβ) peptide and showed favourable impact on the expression of AD-related genes/proteins | Wu et al. [148] |
PLGA and PEG-PLGA nanoparticles | Sonication, solvent evaporation | 1–25 µM | BALB/c mice | Frontal cortex from pup brains | PLGA nanoparticles inhibited β-amyloid (Aβ) peptides aggregation and triggered the disassembly of their aggregates beyond physiological temperatures, protecting neurons against Aβ-mediated toxicity | Paul et al. [109] |